ArriVent BioPharma Elects New Directors, Discloses Officer Compensation
Ticker: AVBP · Form: 8-K · Filed: Apr 28, 2025 · CIK: 1868279
| Field | Detail |
|---|---|
| Company | Arrivent Biopharma, INC. (AVBP) |
| Form Type | 8-K |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, officer-compensation, disclosure
TL;DR
ArriVent BioPharma adds two directors, updates compensation, and files financials.
AI Summary
On April 23, 2025, ArriVent BioPharma, Inc. announced the election of Dr. Jonathan Lim and Mr. David E. Johnson to its Board of Directors. The company also disclosed compensatory arrangements for certain officers and provided a Regulation FD disclosure. The filing includes financial statements and exhibits.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy and governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns board appointments and standard disclosures, with no immediate indication of significant financial distress or operational disruption.
Key Players & Entities
- ArriVent BioPharma, Inc. (company) — Registrant
- Dr. Jonathan Lim (person) — Newly elected Director
- Mr. David E. Johnson (person) — Newly elected Director
- April 23, 2025 (date) — Date of earliest event reported
FAQ
Who were the individuals elected to ArriVent BioPharma's Board of Directors?
Dr. Jonathan Lim and Mr. David E. Johnson were elected to the Board of Directors.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is April 23, 2025.
What are the main items disclosed in this Form 8-K filing?
The filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, Regulation FD disclosure, and financial statements and exhibits.
What is the state of incorporation for ArriVent BioPharma, Inc.?
ArriVent BioPharma, Inc. is incorporated in Delaware.
What is the IRS Employer Identification Number (EIN) for ArriVent BioPharma, Inc.?
The IRS Employer Identification Number (EIN) for ArriVent BioPharma, Inc. is 86-3336099.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 28, 2025 by Dr. Jonathan Lim regarding ArriVent BioPharma, Inc. (AVBP).